Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-071 in scopolamine-induced cognitive impairment
NCT02918266Phase 1Terminated
- Sponsor
- Takeda
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tak-071 in Alzheimer's disease (AD), schizophrenia and dementia with Lewy bodies (DLB) (11 arms), sponsored by Takeda. Primary endpoint: Change From Baseline in Total Number of Errors on the Groton Maze Learning Test (GMLT). Started Nov 2016; status: terminated.
02
Drugs
tak-071
03
Conditions
Alzheimer's disease (AD)schizophreniadementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT02918266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918266.